A new peer-reviewed, nationwide multicenter study published in Obesity Facts directly compared how patients fare on semaglutide versus tirzepatide in the real world — looking at side effects, treatment drop-off rates, and weight loss results across 2,549 people with obesity. For anyone weighing which medication to start or stay on, this is some of the most direct head-to-head evidence yet.
Why Real-World Data Matters
Clinical trials are tightly controlled, but they don't always reflect what happens when a broad population of patients takes a medication in everyday life. This nationwide multicenter observational study set out to fill that gap by tracking patients on both semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (the active ingredient in Mounjaro and Zepbound) under real prescribing conditions. With 2,549 participants, it represents one of the larger direct comparisons of these two drug classes published so far.
The study measured three key outcomes: short-term adverse events (side effects), treatment persistence (whether patients stayed on their medication), and body weight loss alongside metabolic changes. These are exactly the questions patients and their doctors are asking when choosing between the two options.
What the Study Set Out to Measure
Researchers focused on short-term tolerability — meaning the side effects patients experience in the earlier phases of treatment, which are often the reason people stop taking GLP-1 medications before seeing full results. Gastrointestinal issues like nausea, vomiting, and diarrhea are well-known challenges with both drug types. The study also tracked treatment discontinuation rates, which reflect how well patients were able to tolerate their assigned medication over time, as well as body weight loss and broader metabolic outcomes such as blood sugar and lipid changes.
Key takeaway: This 2,549-patient real-world study is one of the first large-scale, direct comparisons of semaglutide and tirzepatide for side effects, persistence, and weight loss — giving patients and prescribers more grounded evidence beyond clinical trial data alone.
What This Means for Patients
Both semaglutide and tirzepatide are approved treatments for obesity and related metabolic conditions, and both work by targeting receptors involved in appetite regulation and blood sugar control. However, tirzepatide acts on two hormone receptors (GIP and GLP-1), while semaglutide targets one (GLP-1). Whether that dual action translates into a meaningfully different side effect profile or better tolerability in a real-world population has been an open clinical question — one this study directly addresses.
If you are currently on one of these medications and experiencing side effects, or if you are considering starting treatment, studies like this one can help inform a more personalized conversation with your prescriber about which option may suit you better.
What to Watch Next
The publication appears in Obesity Facts, a peer-reviewed journal, lending it scientific credibility. However, as an observational study, it cannot prove cause and effect the way a randomized controlled trial can — patient selection, dosing variations, and other real-world factors can influence outcomes. Longer-term follow-up data and additional head-to-head studies will be needed to confirm these findings and extend them beyond the short-term window examined here.
Frequently Asked Questions
This study adds valuable real-world perspective to the semaglutide versus tirzepatide conversation, but individual responses to medication vary widely. Talk with your prescriber or pharmacist about your personal health history, side effect experiences, and treatment goals before making any changes to your medication.
- Peer-reviewed journal article, 'Real-World Comparison of Short-Term Adverse Events, Treatment Persistence, and Efficacy of Semaglutide and Tirzepatide: A Nationwide Multicenter Study,' published in Obes Facts.